NeoGenomics, Inc. (NASDAQ:NEO) Director Lynn A. Tetrault Buys 7,000 Shares of Stock

NeoGenomics, Inc. (NASDAQ:NEO) Director Lynn A. Tetrault acquired 7,000 shares of the stock in a transaction dated Friday, May 9th. The shares were purchased at an average price of $8.14 per share, for a total transaction of $56,980.00. Following the completion of the transaction, the director now owns 7,000 shares of the company’s stock, valued at $56,980. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

NeoGenomics Price Performance

NEO opened at $8.05 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The company’s 50 day simple moving average is $9.21 and its 200-day simple moving average is $13.08. NeoGenomics, Inc. has a one year low of $6.08 and a one year high of $19.12. The stock has a market capitalization of $1.04 billion, a P/E ratio of -12.98 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $168.04 million during the quarter, compared to analyst estimates of $171.38 million. During the same period last year, the business posted ($0.02) earnings per share. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

NEO has been the topic of several analyst reports. Needham & Company LLC lowered their price target on shares of NeoGenomics from $18.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Piper Sandler set a $12.00 price target on shares of NeoGenomics and gave the stock an “overweight” rating in a research report on Tuesday. Morgan Stanley decreased their price objective on NeoGenomics from $17.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, May 1st. Leerink Partnrs cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Finally, Leerink Partners lowered NeoGenomics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $25.00 to $9.00 in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, NeoGenomics presently has an average rating of “Hold” and an average target price of $13.83.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NEO. PNC Financial Services Group Inc. raised its stake in shares of NeoGenomics by 5.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company’s stock worth $257,000 after buying an additional 770 shares during the last quarter. Summit Investment Advisors Inc. raised its position in shares of NeoGenomics by 6.9% during the 4th quarter. Summit Investment Advisors Inc. now owns 13,339 shares of the medical research company’s stock valued at $220,000 after acquiring an additional 863 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after purchasing an additional 1,103 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of NeoGenomics in the 4th quarter worth $26,000. Finally, CWM LLC grew its stake in shares of NeoGenomics by 42.6% during the first quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock worth $60,000 after purchasing an additional 1,883 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.